Published in Br J Haematol on July 01, 1982
Monitoring oral anticoagulation in primary care. BMJ (1996) 2.27
Therapeutic ranges in anticoagulant administration. Br Med J (Clin Res Ed) (1985) 1.40
Factors affecting the maintenance dose of warfarin. J Clin Pathol (1992) 1.40
Fixed minidose warfarin: a new approach to prophylaxis against venous thrombosis after major surgery. Br Med J (Clin Res Ed) (1987) 1.30
Is INR between 2.0 and 3.0 the optimal level for Chinese patients on warfarin therapy for moderate-intensity anticoagulation? Br J Clin Pharmacol (2005) 1.29
Laboratory control of oral anticoagulants. Br Med J (Clin Res Ed) (1987) 1.06
Is the international normalised ratio (INR) reliable? A trial of comparative measurements in hospital laboratory and primary care settings. J Clin Pathol (1999) 0.99
Effect of the choice of WHO International Reference Preparation for thromboplastin on International Normalised Ratios. J Clin Pathol (1993) 0.98
Safety of anticoagulation in the elderly: reasons for discontinuing therapy. Postgrad Med J (1992) 0.75
Reduction of factor VII coagulant activity (VIIC), a risk factor for ischaemic heart disease, by fixed dose warfarin: a double blind crossover study. Br Heart J (1990) 0.75
Monitoring of anticoagulant therapy in heart disease: considerations for the current assays. J Tehran Heart Cent (2010) 0.75
Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest (2001) 3.64
Automated versus manual techniques for the prothrombin time test: results of proficiency assessment studies. Br J Haematol (1978) 3.50
Gastric fibrinolysis. A possible aetiological link with peptic ulcer. Lancet (1967) 3.47
The variability of measurements of the prothrombin time ratio in the National Quality Control Trials a follow-up study. Br J Haematol (1974) 3.42
Effects of low-dose oral contraceptives on blood coagulation. Br Med J (1968) 3.26
Survey of prothrombin time in National External Quality Assessment Scheme exercises (1980-87). J Clin Pathol (1988) 2.98
Progesterone oral contraception and blood coagulation. Br Med J (1969) 2.90
Effect of automation on prothrombin time test in NEQAS surveys. J Clin Pathol (1989) 2.84
Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest (1992) 2.76
Oral contraceptives, blood clotting and thrombosis. Br Med Bull (1978) 2.38
Managing oral anticoagulant therapy. Chest (2001) 2.25
Guidelines on preparation, certification, and use of certified plasmas for ISI calibration and INR determination. J Thromb Haemost (2004) 2.21
The correction of coagulometer effects on international normalized ratios: a multicentre evaluation. Br J Haematol (1994) 2.19
Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest (1998) 2.17
Effects of "natural oestrogen" replacement therapy on menopausal symptoms and blood clotting. Br Med J (1975) 2.06
Effect of international sensitivity index (ISI) of thromboplastins on precision of international normalised ratios (INR) J Clin Pathol (1989) 1.93
Quality control trials of prothrombin time: an assessment of the performance in serial studies. J Clin Pathol (1979) 1.89
Why do outpatients fail to keep their clinic appointments? Results from a survey and recommended remedial actions. Int J Clin Pract (1998) 1.87
Oral anticoagulants controlled by the British comparative thromboplastin versus low-dose heparin in prophylaxis of deep vein thrombosis. Br Med J (1978) 1.83
Coumarin therapy and platelet aggregation. Br Med J (1969) 1.75
The international normalized ratio. A guide to understanding and correcting its problems. Arch Intern Med (1994) 1.66
Platelet aggregation during oral contraception. Br Med J (1969) 1.63
Standardisation of oral anticoagulant treatment. Br Med J (Clin Res Ed) (1984) 1.60
The interpretation of prothrombin results: a national survey. Br J Haematol (1969) 1.59
Assessment of value of calibrated lyophilised plasmas to determine International Sensitivity Index for coagulometers. J Clin Pathol (1992) 1.59
Identification of a congenital defect of factor VII in a colony of beagle dogs: the clinical use of the plasma. J Clin Pathol (1971) 1.56
The British system for anticoagulant control. Thromb Diath Haemorrh (1975) 1.54
Validity of the British system for anticoagulant control using the national reagent. J Clin Pathol (1970) 1.54
Automation and prothrombin time: a United Kingdom field study of two widely used coagulometers. J Clin Pathol (1990) 1.49
Status of present and candidate international reference preparations (IRP) of thromboplastin for the prothrombin time. A report of the Subcommittee for Control of Anticoagulation. Thromb Haemost (1993) 1.45
Therapeutic ranges in anticoagulant administration. Br Med J (Clin Res Ed) (1985) 1.40
Coagulation studies as a prognostic index in acute liver failure. Br J Haematol (1975) 1.39
Abnormal fibrin polymerization in liver disease. Br J Haematol (1976) 1.39
Evidence for the release of gastric fibrinolytic activity into peripheral blood. Gut (1969) 1.34
Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest (1995) 1.24
Laboratory control of anticoagulant therapy. Semin Thromb Hemost (1986) 1.22
Effects of progestogen oral contraception with norethisterone on blood clotting and platelets. Br Med J (1972) 1.18
The bleeding time: current practice in the UK. Clin Lab Haematol (1984) 1.17
Oestrogen-progestogen oral contraception and blood clotting: a long-term follow-up. Br Med J (1971) 1.16
Oral anticoagulants reassessed. Br Med J (Clin Res Ed) (1982) 1.13
The calibration of the second primary international reference preparation for thromboplastin (thromboplastin, human, plain, coded BCT/253). Thromb Haemost (1984) 1.12
Calibration of BCT/441, the ICSH reference preparation for thromboplastin. Thromb Haemost (1986) 1.12
Measuring partial thromboplastin-time. An international collaborative study. Lancet (1976) 1.12
An evaluation of APTT monitoring of low-dose heparin dosage in hip surgery. Thromb Haemost (1982) 1.11
Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results: a rebuttal. J Thromb Haemost (2013) 1.10
An evaluation of chromogenic substrates in the control of oral anticoagulant therapy. Br J Haematol (1981) 1.10
A national standard for anticoagulant therapy. The Manchester comparative reagent. Lancet (1967) 1.10
Blood clotting and platelet aggregation during oral progestogen contraception: a follow-up study. Br Med J (1971) 1.07
Anticoagulants in cardiac infarction. Lancet (1969) 1.07
Laboratory control of oral anticoagulants. Br Med J (Clin Res Ed) (1987) 1.06
Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest (1995) 1.05
Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest (1992) 1.04
Prostacyclin activity in amniotic fluid in pre-eclampsia. Lancet (1980) 1.02
Survey of oral anticoagulant treatment in children. J Clin Pathol (1992) 1.02
Randomized study of adjusted versus fixed low dose heparin prophylaxis of deep vein thrombosis in hip surgery. Br J Surg (1989) 1.01
The partial thromboplastin (cephalin) time test. J Clin Pathol (1972) 1.00
A reliable marker of endothelial cell dysfunction: does it exist? Br J Haematol (1995) 0.99
A double-blind cross-over study of piperazine oestrone sulphate and placebo with coagulation studies. Br J Obstet Gynaecol (1980) 0.99
Effect of the choice of WHO International Reference Preparation for thromboplastin on International Normalised Ratios. J Clin Pathol (1993) 0.98
Comparison of prothrombin complex concentrate and vitamin K1 in oral anticoagulant reversal. Br Med J (1976) 0.97
Inhibition of gastric plasmin activity by epsilon-aminocaproic acid. Ann R Coll Surg Engl (1973) 0.97
Platelet aggregation and strenuous exercise. J Physiol (1971) 0.97
Contemporary laboratory monitoring of low molecular weight heparins. Clin Lab Med (1995) 0.96
A proposed scheme for calibration of international reference preparations of thromboplastin for the prothrombin time. On behalf of the Subcommittee on Control of Anticoagulation. Thromb Haemost (1995) 0.96
Quality control trials in the National Reference Thromboplastin Scheme. Br J Haematol (1973) 0.95
National survey of value of plasma standards for anticoagulant therapy. Br Med J (1968) 0.94
Optimal therapeutic range for oral anticoagulants. Chest (1989) 0.92
College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of oral anticoagulant therapy. Arch Pathol Lab Med (1998) 0.91
Use of factor-VII-rich prothrombin complex concentrate in liver disease. Lancet (1975) 0.91
Antiplasmin concentrations after surgery: failure of alpha 2-antiplasmin to rise in patients with venous thrombosis. Br Med J (1979) 0.91
"Therapeutic range" for oral anticoagulant therapy. Chest (1986) 0.90
Factor VIII assay proficiency assessment: experience in the UK. Scand J Haematol Suppl (1984) 0.89
Factor VII as a marker of hepatocellular synthetic function in liver disease. J Clin Pathol (1976) 0.89
The cause of turbidity in lyophilised plasmas and its effects on coagulation tests. J Clin Pathol (1992) 0.88
Oral anticoagulant therapy and its control: an international survey. Thromb Diath Haemorrh (1975) 0.88
The value of the standardized partial thromboplastin time in detecting heparin during low-dose prophylaxis. Br J Haematol (1979) 0.87
Venous thrombosis and anticoagulant therapy. Br J Haematol (2001) 0.87
Fibrinogen determination in a series of proficiency studies. Clin Lab Haematol (1980) 0.87
System ISI calibration: a universally applicable scheme is possible only when coumarin plasma calibrants are used. Br J Haematol (1997) 0.86
Study of acquired dysfibrinogenaemia in liver disease. Thromb Res (1981) 0.86
The diagnosis of lupus anticoagulants by the activated partial thromboplastin time--the central role of phosphatidyl serine. Thromb Haemost (1984) 0.85
Type I protein S deficiency and skin necrosis. Postgrad Med J (1990) 0.84
Haematology and coagulation indices in paired samples of arterial and venous blood from patients with arterial disease. Haemostasis (1997) 0.84
Results of a multicenter study assessing the status of standardization of a recombinant thromboplastin for the control of oral anticoagulant therapy. Thromb Haemost (1994) 0.83
Association of abnormal fibrin polymerisation with severe liver disease. Gut (1977) 0.81
Co-existent chronic lymphatic leukaemia with polycythaemia vera. Postgrad Med J (1977) 0.81
The APTT monitoring of heparin--the ISTH/ICSH collaborative study. Thromb Haemost (1995) 0.81
Questions and answers on prothrombin time standardisation in oral anticoagulant control. Thromb Haemost (1985) 0.81
The clinical evaluation of International Normalized Ratio variability and control in conventional oral anticoagulant administration by use of the variance growth rate. J Thromb Haemost (2013) 0.80
The multiple faces of the partial thromboplastin time APTT. J Thromb Haemost (2004) 0.80
The use of the British comparative thromboplastin for uniformity of laboratory control of oral anticoagulants. Br J Haematol (1969) 0.80
Proceedings: Abnormal fibrin monomer polymerization in liver disease. Gut (1975) 0.80
The reliability of activated partial thromboplastin time methods and the relationship to lipid composition and ultrastructure. Thromb Haemost (1986) 0.80